Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis

Benzinga Newsdesk www.benzinga.com Neutral 92.5%

Neg 0% Neu 92.5% Pos 0%

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326

Comments

No comments yet. Be the first!